Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 6/20 | 1.00 |
| ▸ | EGFR | P00533 | 14/20 | 0.79 |
| ▸ | GAK | O14976 | 3/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 1/20 | 0.79 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.78 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.78 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.78 |
| ▸ | BUB1 | O43683 | 2/20 | 0.78 |
| ▸ | STK10 | O94804 | 2/20 | 0.78 |
| ▸ | ABL1 | P00519 | 2/20 | 0.78 |
| ▸ | LCK | P06239 | 2/20 | 0.78 |
| ▸ | LYN | P07948 | 2/20 | 0.78 |
| ▸ | RET | P07949 | 2/20 | 0.78 |
| ▸ | SRC | P12931 | 2/20 | 0.78 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.78 |
| ▸ | FECH | P22830 | 2/20 | 0.78 |
| ▸ | KDR | P35968 | 2/20 | 0.78 |
| ▸ | FLT3 | P36888 | 2/20 | 0.78 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1507615 | 0.99 | FBP1 (0.98) | FBP1EGFRGAKALDH1A1MAPT | |
| SCHEMBL1656960 | 0.92 | FBP1 (0.85) | FBP1EGFRGAKALDH1A1MAPT | |
| SCHEMBL14862082 | 0.91 | FBP1 (0.84) | FBP1EGFRGAKALDH1A1MAPT | |
| SCHEMBL4108602 | 0.91 | FBP1 (0.84) | FBP1EGFRGAKALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1507613 | 0.90 | EGFR (0.83) | FBP1EGFRGAKALDH1A1MAPT | |
| SCHEMBL2464248 | 0.89 | EGFR (0.82) | FBP1EGFRGAKALDH1A1MAPT | |
| SCHEMBL667895 | 0.88 | EGFR (1.00) | FBP1EGFRGAKALDH1A1MAPT | |
| Erlotinib SCHEMBL3667407 | 0.88 | EGFR (1.00) | FBP1EGFRGAKALDH1A1MAPT | |
| Erlotinib SCHEMBL29351329 | 0.88 | EGFR (1.00) | FBP1EGFRGAKALDH1A1MAPT | |
| Erlotinib SCHEMBL30362833 | 0.88 | EGFR (1.00) | FBP1EGFRGAKALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-19 | — | — | US | disclosed |
| CN-101163468-A | Novel combination of sulfonamide compounds | EISAI R&D MAN CO LTD (JP) | 2008-04-16 | — | — | CN | disclosed |
| EP-1859793-A1 | NOVEL COMBINATIONAL USE OF SULFONAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-11-28 | — | — | EP | disclosed |
| CN-1066142-C | Quinazoline derivatives | PFIZER (US) | 2001-05-23 | — | — | CN | disclosed |
| CN-1137037-A | Quinazoline derivatives | PFIZER (US) | 1996-12-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EGFR, KIT, ERBB2 | FBP1 2793/4885EGFR 1/4885GAK 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.